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Cutaneous melanoma and uveal melanoma both derive from melanocytes but show remarkable differences in tumorigenesis,
mode of metastatic spread, genetic alterations, and therapeutic response. In this review we discuss the differences and similarities
along with the genetic research techniques available and the contribution to our current understanding of melanoma. The several
chromosomal aberrations already identified prove to be very strong predictors of decreased survival in CM and UM patients.
Especially in UM, where the overall risk of metastasis is high (45%), genetic research might aid clinicians in selecting high-risk
patients for future systemic adjuvant therapies.
1. Introduction
Cutaneous melanoma (CM) has shown to be one of the life-
threatening malignancies with the fastest rise in incidence
over the last decades. The highest incidence of CM is
observed in Australia (60–70 per 100.000 individuals). In
Europe and the USA the incidence is lower (10–15 and 20–
30 per 100.000 [1, 2], resp.). CM accounts for more than
90% of all melanomas [3], whereas uveal melanoma (UM)
is only encountered in 5% [4]. Nevertheless, UM is the most
frequently occurring intraocular malignancy (85%) in the
western world. Although CM and UM both derive from
melanocytes, these two distinct tumors show remarkable
differences in tumorigenesis, mode of metastatic spread,
genetic alterations, and therapeutic response [5, 6]. CM can
occur anywhere on the body but is predominantly observed
in sun-exposed body parts. This partly explains the high
incidence of CM in the light-skinned residents of Australia
and New-Zealand. UM can occur anywhere along the uveal
tract but tend to occur more frequently in the choroid (80%)
and the ciliary body (15%) (Figure 1). The incidence of UM
appears to be relatively stable with around 7 new patients
per 1 million individuals yearly in the western world. UV-
light exposure has shown not to be of specific risk in UM.
However recently, Schmidt et al. [7] demonstrated a positive
interaction between UM and individuals with light colored
eyes who sustained frequent UV-radiation. In addition, the
tendency of iris melanomas to occur in the lower half of the
iris has been explained by the increased sunlight exposure
of this area [8]. Other known risk factors for CM and UM
are fair skin type (CM and UM), familial occurrence of
melanoma (CM) [9], number of melanocytic naevi (CM),
light colored eyes (UM), and oculodermal melanocytosis
(UM) [10, 11].
2. Diagnostics
Clinical examination of suspicious lesions remains an impor-
tant modality in diagnosing CM and UM. As for the
diagnosis in CM, dermatologists rely mostly on clinical
examination and reserve (excisional) biopsy for tumors of
uncertain origin. Only UM of the iris can be diagnosed
by external examination and is therefore detected in an
early stage. For detection of UM of the choroid or ciliary
body, a thorough ophthalmic examination including indirect
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ophthalmoscopy and ultrasonography of the retina has to
be conducted. Tumor growth can lead to retinal detachment
and result in extraocular extension of the tumor. At this
point, defects in visual field or central vision may be present.
Early symptoms of tumor growth, however, can be vague or
absent to the patients’ notion.
The overall survival is known to be dependent of the
tumor thickness (CM) and largest tumor diameter (UM) at
time of diagnosis. Therefore, clinicians still concentrate on
early detection of CM and UM. This resulted in an average
tumor thickness of 0.76 mm in CM at time of diagnosis
nowadays. This was shown to relate to an overall 10-year
survival of 90% [12] of these small lesions. Similarly, UMs
with a diameter of under 4 mm relate to a 5-year survival
of 84%. The 5-year survival rate for medium-sized UM (4–
8 mm in diameter) is 68%, and 47% with large size UM (over
8 mm in diameter) [13]. The survival of CM and UM patients
with metastatic disease is however equally bad with a dismal
mean of 2–7 months [14–16].
3. Therapy
The most frequently used therapeutic option in CM is
excision of the primary tumor and enucleation of the tumor
containing eye in case of large UM. Most small and medium-
sized UMs are currently managed by eye-saving treatments
such as observation (small inactive tumors), episcleral
brachytherapy or charged-particle radiotherapy, and several
other variants of radiotherapy. In CM, radiotherapy is only
used for palliative purposes as CM cells appear to be relatively
radio-resistant. Adjuvant systemic therapy is mainly used
in patients at high-risk of metastasis or in patients who
already have developed metastasis. The response rates of
chemotherapeutic agents in metastasized CM and UM are
however as low as 7%–25% [17–20].
4. Metastasis
Both malignancies display a strong tendency to metastasize
[3]. Although the mode of metastatic spread is different,
CMs tend to metastasize by both hematogenous and lym-
phogenous route and local invasion. CMs are known to
be able to give rise to metastases in skin (13%–38%), dis-
tant lymph nodes (5%–34%), distant subcutaneous tissues
(32%), lung (18%–36%), liver (14%–20%), CNS (2%–20%),
and/or bone (4%–17%) [21]. In UM, metastatic spread is
almost exclusively by hematogenous route to remote organs
of which the liver is involved in almost all cases (90%)
[15, 22]. The reason why UM is not involved in metastatic
spread by lymphogenous route is thought to be a direct result
of the absence of draining lymphatics of the eye [6, 23]. It
is however still unknown why the liver is especially affected
by metastases although there are reports about sporadic
metastases in lung (24%) and bone (16%) [24–27].
Eventually 45% of UM patients die of metastasis regard-
less of enucleation or radiotherapy [16]. This has led to
theories about the early presence of micrometastasis in the
disease process, which remain dormant for years before they
give rise to clinically detectable macrometastasis [28]. The
exact duration of this proposed state of dormancy and cues
for metastatic development remains uncertain. Shields et
al. [29, 30] reported tumors with a size of just 1.0 mm
to be capable of metastasizing, hence the need for highly
specific and sensitive prognostic markers to predict which
patient is at risk of developing metastasis. In the quest
for significant prognostic markers in UM, already several
have been identified. Age (over 60 years), largest basal
tumor diameter (over 18 mm), tumor cell type (epitheloid
cellularity), and closed vascular patterns correlate with early
metastatic disease and shorter survival [31–33]. In CM,
tumor thickness (increasing Breslow thicknesses), level of
invasion, age (old age), gender (males), anatomic site of
primary tumor (head/neck or trunk), number of metastatic
lymph nodes, and ulceration on histopathological research
appeared to be independent significant prognostic factors
of early metastasis [21]. These factors are summarized in
a staging system known as the TNM-staging system. This
system relies on tumor stage at time of diagnosis which has
shown to be the most important prognostic factor in CM
and is now widely used for prognostic purposes and clinical
decision making [34].
5. Tumor Research Methods
Genetic analysis of tumor material, either from excised CM
or from enucleated eyes, has led to the identification of
genetic prognostic markers for both types of melanoma.
In the past years several cytogenetic and molecular
genetic techniques have been used to investigate the genomic
background of melanomas. With conventional karyotyping,
we and others were able to identify chromosomal gains,
losses, and translocations in UM (Table 1). Comparative
Genomic Hybridization (CGH) allows a complete copy
number analysis of the entire genome by comparative
hybridization of differentially labelled genomic sample and
reference DNA to normal human metaphase spreads. Both
these techniques have a low resolution of 5–20 MB. Fluo-
rescence in situ Hybridisation (FISH) provides a higher test
resolution and even clonal gains and losses present in only
a low percentage of tumor cells can be detected [35, 36].
Furthermore, FISH has high test specificity, and although
time consuming, still it is a frequently used technique in
tumor research and diagnostics. Also paraffin-embedded
tissue sections can be assayed by FISH. A drawback to
this technique, however, is that only a small number of
loci can be analyzed in one single experiment. Molecular
genetic techniques such as multiplex ligation-dependent
probe amplification (MLPA) and microsatellite instability
analysis (MSI) require input of isolated DNA and enable
analysis of multiple loci in one experiment with a high
resolution.
MLPA is a polymerase chain reaction- (PCR-) based tech-
nique which functions through the simultaneous hybridiza-
tion of multiple (up to 50) probes to tumor DNA. Each
probe with unique length is only amplified when ligated to
its unique probe-counterpart. This provides high specificity
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Figure 1: Uveal melanoma located in: iris (a), ciliary body (b) and choroid (c).
Table 1: Overview of techniques used in (molecular) cytogenetics.
Method Resolution Provides genome wide testing? Detection balanced anomalies? Detection unbalanced anomalies?
Karyotype ∼5–10 Mb + + +
G-banding
FISH ∼100 kb − + +
SKY ∼1-2 Mb + + +
MSI <1 kb − − +
CGH ∼5–20 Mb + − +
MLPA ∼1–40 kb − − +
SNP/ CGH array >100 kb + − +
of hybridized probes. The final amount of DNA, after
several PCR-cycles, is dependent of its initial quantity and
eventually copy number changes can be quantitated by
relative quantification (RQ). MLPA has proven to be a
suitable test for detection of chromosomal anomalies in
tumor material [37].
For loss of heterozygosity (LOH) analysis, MSI is
frequently used. With this technique, specific markers
are required which are allowed to hybridize to the so-
called microsatellites within genomic intronic DNA. These
microsatellites are tandem repeats of simple polymorphic
sequences that are randomly distributed and allow detection
of the presence or absence of two different alleles. A drawback
to this technique is that only a limited number of markers can
be analyzed in a single experiment.
Microarray-based CGH, single-nucleotide polymor-
phism (SNP) arrays, and gene expression analysis are among
the most frequently applied array-based techniques nowa-
days. All these techniques are based on series of DNA seg-
ments (oligonucleotides or bacterial artificial chromosomes;
BACs) orderly arranged on a chip, to which fluorescently
labeled DNA or RNA can be hybridized. This enables
the analysis of copy number status or gene expression of
one entire genome very rapidly. Nowadays, there are chips
available which enable analysis of structural variation at high
level of detail with up to 1.2 million markers. The use of SNP
arrays can also provide evaluation of loss of heterozygosity or
isodisomy of parts of the genome.
Drawbacks to array technology are its cost, which is
about tenfold compared to FISH, and the inability to
detect balanced anomalies and genomic abnormalities in
frequencies below 10% of analyzed nuclei. Table 1 provides
an overview of the differences in resolution and detection
limits among the cytogenetic and array-based techniques.
The different research techniques previously mentioned
certainly contributed to our understanding of melanoma by
identification of chromosomes and genes involved in the
disease. In the following section we will discuss the most
important chromosomal and genetic alterations UM and
CM.
6. Chromosomal Aberrations in UM
6.1. Chromosome 3. The most frequently encountered chro-
mosomal aberration in UM is loss of one of the two copies
of chromosome 3 (monosomy 3 or −3). Monosomy 3 is
observed in approximately 50% of cases [38–41] and appears
rather specific for UM as this chromosomal anomaly is rarely
encountered in CM or other cancer types [42] (Figure 2).
Several groups have already shown that there is a strong
correlation between monosomy 3 and the development
of metastatic disease [43–46]. In addition, monosomy 3
strongly relates to several clinical and histopathological
parameters such as epithelioid cytology, closed vascular
patterns, large tumor diameter, and ciliary body involvement
[41, 44, 47, 48]. Also, monosomy 3 is thought to represent
an early event in tumorigenesis because the alteration
is frequently seen in combination with all other known
chromosomal abnormalities [49]. In 5%–10% of cases one
copy of chromosome 3 is lost and the remaining copy is
duplicated. This isodisomic state of chromosome 3 appears
to be prognostically equivalent to monosomy 3 [50]. Rarely,
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partial deletions of chromosome 3 are found [26], and
although this has hampered fine mapping studies, a common
region of allelic loss on 3p25 and on 3q24–q26 could be
defined [50, 51]. Most likely these regions harbor putative
tumor suppressor genes but no specific genes have yet been
identified.
Gene expression profiling on UM tumor material does
show promising results. By this technique UMs were found
to cluster naturally in two distinct molecular classes (class
I or class II) based on classifier gene sets [52]. Both classes
appear to have clinical prognostic relevance; patients with
class I tumors rarely die of metastases, while patients with
class II tumors have a high risk of death due to metastases
[33, 53]. Onken et al. [54] reported an eight-year survival
of 95% for patients with class I UM and 31% for patients
with class II UM. Moreover, class II tumors display the
previously identified poor prognostic factors: monosomy 3,
epitheloid cytology, and closed vascular patterns. The strong
significant relation between molecular class and survival
indicates that array technology clearly outperforms clinical
and histopathological parameters [53–56].
6.2. Chromosome 8. Gain of 8q (+8q) is found in around
40% of UM cases and proved to be an independent
significant prognostic marker for decreased survival [43, 45].
It frequently occurs in combination with monosomy 3,
either as +8q or as isodisomy 8q, and this combination also
shows a strong relation with metastatic disease [43–45, 57].
Abnormalities of chromosomes 3 and 8 are more common
in ciliary body-located UMs; whilst alterations of the long
arm of chromosome 8 tend to relate to choroid-derived UMs
[43, 46, 48, 49]. However, in the study by Kilic et al. [58],
chromosome 8q abnormalities were shown to correlate with
large tumor diameter but there was no significant relation
found between gain of 8q and the metastatic phenotype by
univariate analysis. Gain of 8q is also frequently observed
in different copy numbers in different UMs, therefore this
is speculated to be a late event following the initiation of
monosomy 3. The common region of amplification was
found to range from 8q24.1 to 8q24.3 [59, 60]. Although
gain of chromosome 8q is observed in 25% of CMs, the
simultaneous occurrence of monosomy 3 and gain of 8q,
as in UM, is rarely observed in CM. Several oncogenes
on chromosome 8q were hinted as possible factors in UM
pathogenesis; among these genes are MYC (on 8q24), NBS1
(on 8q21), and DDEF1(on 8q24) [46, 61–64]. A potential
metastasis suppressor gene located on 8p21, named LZTS1,
has been pointed out by Onken et al. [23].
6.3. Other Chromosomal Aberrations in UM. Kilic et al. [65]
showed loss of 1p36 in combination with monosomy 3 to
be of prognostic significance: these aberrations occurring
together display a stronger correlation with decreased sur-
vival than monosomy 3 or loss of 1p36 alone (−1p36 by itself
is not of prognostic significance). One of the suggested tumor
suppressor genes in the 1p36 region, APITD1, was found to
be not of significance in patients survival [66]. The common
deleted regions on chromosome 1 were found to range from
1p34.3 to 36.2 [48, 67].
Alterations of chromosome 6 are frequently encountered
in both UM & CM (discussed later) but show less prognostic
value compared to monosomy 3 or gain of 8q in UM
[42, 46]. Of these alterations, gain of DNA-material on the
short arm of chromosome 6 (+6p) is found in 25%–29%
of UM and relates to spindle cell cytology and low risk
for development of metastasis [33, 42, 49, 68, 69]. Hughes
et al. [60] reported the shortest region of overlap on the
p-arm on chromosome 6 to be restricted to 6p22.3–p25.
The simultaneous occurrence of +6p and −3, however, is
rarely observed. Loss of DNA material on the long arm
of chromosome 6 (−6q), observed in 25%–38%, possibly
represents another late event in tumorigenesis and correlates
with worse prognosis [39, 42, 48, 69, 70]. The region of
common deletion on the long arm was found to range from
6q16.1 to 22.3 [60].
Infrequently, abnormalities of the other chromosomes
such as loss of 9p, loss of chromosome 10, loss of 11q23–
q25, and gain of chromosomes 7 and 10 have been reported
[39, 40, 44, 46, 47] but a possible role in tumorigenesis and/
or development of metastasis in UM has yet to be evaluated.
6.4. Genes. Much less is known about genes involved in the
development and progression to metastasis in UM compared
to CM. This is mainly the result of the lower incidence of
UM and the small quantities of tumor sample available for
research. While there are many different potential tumor
genes identified in CM every year, UM lags behind. However,
several candidate genes were proposed in UM recently, such
as GNAQ, DDEF1, NBS1, HDM2, BCL-2, and CCND1. For
most of these genes, a definite role in tumorigenesis or
progression towards metastasis has to be validated.
G protein alpha subunit q (GNAQ) is the first gene
found to be mutated frequently in UM. Several groups have
shown that approximately 46% of UMs carry mutations
in the GNAQ gene [27, 81, 104] (Table 2) turning GNAQ
into an oncogene. This oncogenic conversion leads to
constitutive activation of the MAP-kinase pathway which
results in a situation in which the cell is provided continuous
growth signals in the absence of extracellular stimuli [113]
and thus cell proliferation. GNAQ status was found not
to be correlated with disease free survival; so it could
represent an early event in tumorigenesis [27, 104]. This
mutation is also found in 83% of blue naevi of the skin
[81].
Furthermore, the DDEF1-gene has been described in
UM. It is located on 8q24 and found to be mutated in
50% of UMs leading to overexpression [69]. High expression
of DDEF1 was shown to result in more motile low-grade
UM cells by Ehlers et al. [63] and could therefore be
important in metastatic development [63, 114, 115]. The
NBS1-gene is found to be overexpressed in 50% of UM
[62]. The encoded protein product is postulated to be part
of a complex involved in DNA-repair [102]. It is theorized
that overexpressed NBS1 could allow UM progression by
promoting the repair of DNA damage which occurs more
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Figure 2: Chromosomal aberrations in cutaneous melanoma (CM) and uveal melanoma (UM): Based on all cases in the Mitelman Database
of Chromosome Aberrations in cancer by Ho¨glund [42].
6 Dermatology Research and Practice
Table 2: Commonest known genetic changes in CM and UM.
CM
Gene Mechanism Location Cases (%) Reference
Proto oncogenes
NRAS mutation 1p13 15–25 [71, 72]
AKT3 amplification 1q44 40–67 [73]
BRAF mutation 7q34 36–61 [74–76]
NBS1 amplification 8q21 ∗ [77]
MYC amplification 8q24 1–40 [78–80]
DDEF1 amplification 8q24 —
GNAQ mutation 9p21 83∗
1
[81]
CCND1 amplification 11q13 6–44 [82–84]
HDM2 amplification 12q15 —
BCL-2 amplification 18q21 >90% [85, 86]
Tumor suppressor genes
LZTS1 deletion 8p21 —
CDKN2A-sporadic deletion, mutation 9p21 ∗ [87]
CDKN2A-familial deletion, mutation 9p21 30–80 [88–91]
PTEN deletion, mutation 10q23 10–40 [92–94]
UM
Gene Mechanism Location Cases (%) Reference
Proto oncogenes
NRAS mutation 1p13 ∗ [95–98]
AKT3 amplification 1q44 —
BRAF mutation 7q34 48∗
2
[81, 99–101]
NBS1 amplification 8q21 50 [62, 102]
MYC amplification 8q24 43 [103]
DDEF1 amplification 8q24 50 [63, 69]
GNAQ mutation 9p21 46 [81, 104]
CCND1 amplification 11q13 65 [69, 105–107]
HDM2 amplification 12q15 97 [69, 105, 106]
BCL-2 amplification 18q21 100 [105, 108, 109]
Tumor suppressor genes
LZTS1 deletion 8p21 — [23]
CDKN2A-sporadic deletion, mutation 9p21 ∗ [110]
CDKN2A-familial deletion, mutation 9p21 ∗ [110]
PTEN deletion, mutation 10q23 15 [111, 112]
— no data available.
∗Rarely observed or sporadic reports in literature.
∗1 Observed in 83% of blue naevi.
∗2 Observed in 48% of iris melanomas.
frequently in advanced tumors with increased genetic insta-
bility. High expression of the HDM2-gene on 12q15 is found
in 97% of UM [69]. High HDM2 expression was shown to
inhibit p53 and its function of eliminating abnormal cells
[105, 106]. An elevated expression of BCL-2, located on
18q21, is observed in UM but also in normal melanocytes.
This overexpression is reported to block apoptosis [105,
106, 108, 109] and is suggested to be responsible for the
resistance to chemotherapy or irradiation of melanocytes
[69, 116]. In 65% of UM cases, CCND1 is reported to be
overexpressed. Overexpression of CCND1 leads to activation
of cyclin dependent kinases (CDKs) which consequently
phosphorylate and inactivate Rb [69, 106, 107]. The CCND1
overexpression is associated with large tumor size, epitheloid
cytology, and poor prognosis [106].
7. Chromosomal Aberrations in CM
CMs display a more complex karyotype compared to UM.
The most frequently observed chromosomal aberration in
CM is monosomy 10. This aberration is found in approxi-
mately 60% of CM cases and appears to be significantly more
frequent compared to UM, where monosomy 10 is found in
27% of cases [42] (Figure 2). Because monosomy 10 could
include loss of tumor suppressor genes, much research has
been aimed at identifying possible tumor suppressor genes
involved. Phosphatase and tensin homolog (PTEN) is one
of the identified tumor suppressor genes, located on 10q23,
with strong evidence for a role in CM tumorigenesis [92]
(Table 2). PTEN is thought to be inactivated by deletion
or mutation and through loss of its negative regulatory
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effect on AKT, lead to activation of the AKT-pathway,
and consequently prevent apoptosis [85, 111]. The actual
inactivation of PTEN is observed in up to 30%–40% of CM
cell lines [92, 93], but only in 10% of primary CMs. PTEN
inactivation or downregulation is mainly found in tumors
with an increase in aneuploidy, suggesting that it is a late
event in tumor progression [27, 111]. In UM, inactivation
of PTEN is reported in 15% of cases and has been linked
to an increase in aneuploidy but also poor clinical outcome
[111, 112].
The other frequently reported chromosomal aberrations
involved in CM are −1p, +1q, −4, −5, −6q, +7, −9p,
−11q, −12q, −14, −15, −16, −17p, +18, +20, −21, and −22
[42]. Some of them will be discussed here along with the
most well-known genes, involved in tumorigenesis and/ or
metastatic development.
7.1. Chromosome 1. Rearrangements of the distal part of the
short arm of chromosome 1, leading to loss or gain of 1p,
are reported in 28% and, respectively, 33% of CMs. Several
regions along chromosome 1 are of specific interest because
they harbor the NRAS- and AKT3-gene. NRAS is located
in the 1p13-region and shown to be activated by mutation
in 15%–25% of CMs [71, 72]. NRAS is believed to be also
involved in the MAP-kinase pathway. Activation of NRAS
leads to activation of the MAP-kinase pathway and as a result
cellular proliferation. Additionally, NRAS binds and acti-
vates lipid kinase phosphoinositide-3 kinase (PI3K), thereby
activating the AKT-pathway and preventing apoptosis [85].
A direct activating mutation of the AKT3-gene located on
1q44 is found in 40–67% of CMs [73]. Overexpression of
AKT3 renders cells less sensitive to apoptotic stimuli and
as mentioned before; PTEN inactivation can lead to the
selective activation of AKT in CMs [92]. Different groups
have shown NRAS mutations to be very rare in UM [95–98].
7.2. Chromosome 6. Alterations of chromosome 6 are
reported in a total of 66% of CMs, of which +6p is observed
in 24% and −6q in 42% [42]. Of these alterations, the 6q10–
q27 region shows the highest frequency of rearrangements as
a result of deletion, translocation, or due to the formation
of an isochromosome of its short arm. The region on the
short arm of chromosome 6 that frequently shows alterations
spans from 6p21 to 6p25 and mainly results in gain of DNA
material. Up till now, there have not been reports about
possible over- or underexpressed genes on chromosome 6
involved in tumorigenesis. As mentioned before, both +6p
and −6q are common in UM. The prognostic value of these
alterations, however, proved to be lower than in CM [42, 46].
7.3. Chromosome 7. In 36% of CMs, gain of DNA-material
on both arms of chromosome 7 is observed. Most frequently
described are somatic mutations within the 7q34 region,
where the BRAF-gene is located. Up to 60%–70% of CMs
are characterized by activating mutations in BRAF [74].
The BRAF-gene encodes a kinase involved in the MAP-
kinase pathway which, by mutation, is thought to lead
to constitutive activation of the aforementioned pathway
[117] and cell proliferation. A single substitution (p.V600E)
appears to account for more than 90% of all BRAF mutations
[118]. The same mutation is also found in 80% of benign
naevi and is therefore believed to be an early event in
melanomagenesis [75]. There is however evidence from
another study that indicates a role in later stages of tumor
growth and development [76]. Mutations of BRAF were
shown to be absent in UMs [95, 99]. But in a small study,
BRAF mutations were shown to occur in 48% of UM of the
iris [100].
7.4. Chromosome 9. Chromosomal aberrations on chromo-
some 9 presenting as either deletions of the short arm,
−9p10–24 (37% of CMs), or long arm, +9q22–34 (15% of
CMs), have been reported. One of the best characterized
genes in CM is CDKN2A, located on 9p21. Inactivating
mutations, or loss, results in inactivation of the two encoding
tumor suppressor genes p16 and p14. Both genes were
already related to high susceptibility for CM and were found
in a total of 30%–80% of familial CM [88–90]. These
mutations are however rarely observed in sporadic CM [87]
or UM [110].
8. Epigenetics
Over the last years, there have been growing interest for
the role of epigenetics in CM and UM pathogenesis and
metastasis. The most well-known epigenetic features are
methylation and microRNAs (miRNAs). Both act through
different mechanisms by which they are thought to alter nor-
mal gene transcription. Methylation is frequently reported
to induce silencing of certain genes by direct methylation
of DNA strands or hypermethylation of specific promot-
ers. Because human cancers are theorized to cause global
demethylation and promoter hypermethylation, it is thought
that this could lead to activation of imprinted genes and the
inactivation of genes [119]. In CM, several genes commonly
hypermethylated have been identified such as RASSF1A,
APC, PYCARD, RARB, MGMT, DAPK, 3-OST-2, HOXB13,
SYK, TIMP3A, CDKN2A, FHIT, SOCS1, SOCS2, and PTEN.
In UM, the studies regarding gene/promoter methylation
status are still limited but CDKN2A is found to be methylated
in 33% of cases [120, 121]. Similarly, RASSF1 appears to
be methylated in 13%–70% [122] and hTERT in up to
52% [123]. It is not certain whether these methylated sites
contribute to metastasis.
MiRNAs have recently come to the attention because of
their inhibitory effect on translation of mRNAs into proteins.
Although there are limited studies available on the role of
miRNAs, several miRNAs have been marked as possibly
involved in UM tumorigenesis and/or metastasis such as let-
7b, miR18a, miR-199a, miR495, miR549, and more [124,
125]. Worley et al. [124] and Radhakrishnan et al. [125]
reported differentially expressed sets of miRNAs that could
accurately distinguish two different classes with a low- and
high- risk potential for metastatic disease. These miRNAs
were shown to bind to genes often found to be deleted in
UM such as 8p22, but also 13q and 17p. In CM, many
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different miRNAs have been identified such as miR-137, miR-
182, miR-221, miR-222, and different subtypes of the let-
7 family [126–129]. These are thought to act as important
factors in CM tumorigenesis and metastasis; further research
is however required to analyse their exact role in CM.
9. The Relation between CM and UM
Although there are many differences between CM and UM,
they do share some features. First of all, both tumors
derive from neural crest melanocytes which migrated to the
epidermic tissue or the eye. This common origin is still
observed on morphologic and gross histopathologic research
of tumor material from CM and UM. The chromosomal
regions frequently observed to be amplificated or deleted in
both melanotic tumors do resemble each other although the
exact frequencies in which they occur differ. For instance,
monosomy 3 is observed in around 50% of UMs and in 25%
of CMs. The same holds for gene expression status: many
of the genes found to be frequently overexpressed or under-
expressed in CM are also observed in UM. Furthermore,
both tumors are highly metastatic which is illustrated by the
early initiation of metastases. UM, however, is not known to
spread by lymphogenous route as CM is. This is an important
difference and possibly due to the anatomical restrictions
of the eye and the lymphatic system. Another difference
concerns the role of UV-radiation, which appears to be an
important risk factor for the development of CM but is not
known as a risk factor for development of choroid-localized
UM. There is however evidence regarding an interaction
between UV-radiation and development of UM in the easily
to sunlight exposed iris [7].
Maybe the two types of melanotic tumors are more
similar than previously thought because of its common
origin and the differences are merely a result of the exact
location of the melanoma and its direct environment. Each
location has its own array of carcinogens to which the tissue
is exposed to. For instance, the retina is less intensely exposed
to UV-radiation than the skin. The epithelial environment
the cutaneous melanocytes reside in leads to the cells having
more epithelial qualities of which downregulation of the
molecule E-cadherin during local invasion is an example.
Uveal melanocytes do not require this “mesenchymal to
epithelial transition” because they are not in an epithelial
environment. This could for part explain the differences
in the spectrum of mutations between the two types of
melanocytic tumors.
10. Conclusion
Despite all developments in diagnostics and therapeutics of
primary UMs in the last 20–30 years, there have been no
significant decrease in metastasis-related deaths [6, 130]. The
prognosis for patients with metastasized disease still is 2–
7 months, regardless of systemic therapy. This is probably
due to the early initiation of metastasis in both CM and
UM, which underlines the need for early prognostication.
This could, at least for part, be achieved by continuing
the search for prognostic factors in CM and UM through
genetic research on tumor material. Genetic research has
showed us that CM and UM have aberrations in common
but that these differ in frequency between the two tumors.
Even so, both express many of the same genes but not all.
In CM, alterations of chromosomes 1, 6, 7, 9, 10, 14, 16,
and 21 are frequently observed and already several candidate
genes and proteins involved in the tumorigenesis of CM
have been identified. UMs were shown to frequently display
chromosomal aberrations on chromosomes 1, 3, and 8. Of
these, monosomy 3, gain of 8q, and the combination of
loss of 1p36 and monosomy 3 appeared to be significant
prognostic factors for decreased survival; There have not
been identified genes yet that are prognostically active in
UM, and at this point developments in UM lag behind
compared to CM. New insights in UM, however, came about
by gene expression profiling of UMs which were shown to
cluster naturally in two classes with different prognosis [52–
54]. Generally, array technology has proven to outperform
clinical and histopathological parameters in determining a
patients’ prognosis. This led to the frequent usage of gene
expression testing in the current clinical setting in an attempt
to identify high-risk patients. We do have to remind that
we do not yet know whether monosomy 3 and classifier
genes are truly involved in tumor progression and metastatic
potential or that those are merely markers of the underlying
cause. Additionally, we have to evaluate whether these results
may aid clinicians in assessing eligibility of patients for future
(adjuvant) systemic therapies. Most of the genetic research
is conducted on relatively large UMs because small UMs
are treated conservatively and this has biased UM research.
Recent groups already reported about the suitability of fine
needle aspiration biopsy in harvesting of tumor material
from patients treated with eye-saving modalities [131–134].
Also for this diagnostic option we have to evaluate whether
this will be beneficial for patient care and can lead to
predictions about prognosis for the individual patient. Some
genetic markers have already proven its value in predicting
prognosis next to clinical and histopathological markers
and could lead to selection for patient-tailored therapies
in the near future. Also, the challenge will be to prove or
disprove the cost-effectiveness of array technology and find
additional genetic markers predictive of worse prognosis in
CM and UM patients. Concluding, much information has
been gained by genetic research of melanonomas and further
research could augment our knowledge. Because there are
similarities between the two tumors, research on one of
two tumors could provide clues for research on the other.
Epigenetics, the whole new field in genetic research, does
look like a promising ally in our quest to understanding
of pathogenesis and metastasis in CM and UM and might
provide us with valuable prognostic information in the near
future.
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